Printer Friendly

BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES EXTENSION OF NUCLEOLYSIN DISTRIBUTION AGREEMENT

 LYNBROOK, N.Y., May 20 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has reached an agreement with its Swiss licensee to extend their agreement to seek approval and distribute Nucleolysin in Switzerland and Italy for the treatment of herniated spinal discs. In consideration of this extension, BioSpecifics will be paid $210,000 at certain milestone dates as an advance against future orders.
 BioSpecifics also announced the receipt of delibazione clearances in Italy for Nucleolysin and for Collagenase ointment. These authorize the conduct of clinical trials in Italy. The Italian market is considered to be substantial for both of these treatments.
 BioSpecifics, through its subsidiaries, produces and licenses pharmaceutical products for domestic and international sales. The company's current principal product is its FDA approved enzyme Collagenase ABC, used in topical applications for treatment of dermal ulcers and severely burned areas. The company is also engaged in various stages of research, development, clinical testing and licensing of additional pharmaceutical products.
 -0- 5/20/93
 /CONTACT: Edwin H. Wegman, president of BioSpecifics, 516-593-7000; or Sam Witchel of Scharff, Witchel & Co., 212-983-1060, for BioSpecifics/
 (BSTC)


CO: BioSpecifics Technologies Corp. ST: New Jersey IN: MTC SU:

GK-TS -- NY080 -- 0827 05/20/93 13:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 20, 1993
Words:203
Previous Article:IMC FERTILIZER'S 10-Q FILING DISCLOSES NEW LITIGATION AND FINANCIAL CONDITION; WAIVERS AND COMMITMENTS FROM LENDERS ANNOUNCED TODAY
Next Article:DIGICON INC. TERMINATES DISCUSSIONS WITH GRANT TENSOR GEOPHYSICAL CORP.
Topics:


Related Articles
BIOSPECIFICS TECHNOLOGIES EXPLORES LICENSING OF PHARMACEUTICAL PRODUCTS TO IVAX
BIOSPECIFICS TECHNOLOGIES CORP., ANNOUNCES APPLICATION FOR NEW DRUG APPROVAL IN GERMANY
BIOSPECIFICS TECHNOLOGIES CORP., ANNOUNCES SEVEN MAJOR U.S. BURN CENTERS TO PARTICIPATE IN CLINICAL TRIALS OF HIGH POTENCY BURN TREATMENT
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES FOURTH QUARTER AND YEAR-END RESULTS FOR FISCAL 1995
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SUCCESSFUL COMPLETION OF NUCLEOLYSIN CLINICAL TRIAL IN ITALY
BIOSPECIFICS TECHNOLOGIES CORP., ANNOUNCES RESULTS FOR THE FIRST QUARTER ENDED APRIL 30,1995
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES COLLAGENASE OINTMENT LICENSE AGREEMENT IN GERMANY
BioSpecifics Appoints Asante Partners LLC as Strategic Advisor; Asante to Assist the Company in Evaluating Strategic Opportunities.
BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC.
BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters